#mabs — Public Fediverse posts

HPLC Buffers Market in Egypt | Report – IndexBox https://www.byteseu.com/1919044/ #BiomoleculeSeparation(peptides #BiopharmaMarketReport #DrugSubstancePurityTestingAndRelease #Egypt #forecast #HPLCBuffers #HydrophilicInteractionChromatography(HILIC) #ImpurityProfilingAndForcedDegradationStudies #IonChromatography #mAbs) #MarketAnalysis #oligonucleotides #PharmacokineticAndMetabolomicAnalysis #ReversedPhaseHPLC/UHPLC #SizeExclusionChromatography(SEC)

https://www.europesays.com/africa/171823/ HPLC Buffers Market in Egypt | Report – IndexBox #BiomoleculeSeparation(peptides #BiopharmaMarketReport #DrugSubstancePurityTestingAndRelease #Egypt #forecast #HPLCBuffers #HydrophilicInteractionChromatography(HILIC) #ImpurityProfilingAndForcedDegradationStudies #IonChromatography #mAbs) #MarketAnalysis #oligonucleotides #PharmacokineticAndMetabolomicAnalysis #ReversedPhaseHPLC/UHPLC #SizeExclusionChromatography(SEC)

Porcine #influenza #mAbs to #H3, #H5, and #H7 hemagglutinins recognize H3 egg adapted site and target the HA stem, https://etidiohnew.blogspot.com/2026/03/porcine-influenza-mabs-to-h3-h5-and-h7.html

Porcine #influenza #mAbs to #H3, #H5, and #H7 hemagglutinins recognize H3 egg adapted site and target the HA stem, https://etidiohnew.blogspot.com/2026/03/porcine-influenza-mabs-to-h3-h5-and-h7.html

Porcine #influenza #mAbs to #H3, #H5, and #H7 hemagglutinins recognize H3 egg adapted site and target the HA stem, https://etidiohnew.blogspot.com/2026/03/porcine-influenza-mabs-to-h3-h5-and-h7.html

Porcine #influenza #mAbs to #H3, #H5, and #H7 hemagglutinins recognize H3 egg adapted site and target the HA stem, https://etidiohnew.blogspot.com/2026/03/porcine-influenza-mabs-to-h3-h5-and-h7.html

Porcine #influenza #mAbs to #H3, #H5, and #H7 hemagglutinins recognize H3 egg adapted site and target the HA stem, https://etidiohnew.blogspot.com/2026/03/porcine-influenza-mabs-to-h3-h5-and-h7.html

🧬 One amino acid to stabilize them all — myth or molecular reality?

🔗 Single-residue engineering of lambda (λ) antibody light chains reduces conformational flexibility and enhances thermal stability. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.10.045

📚 CSBJ: https://www.csbj.org/

#MonoclonalAntibodies #mAbs #Immunology #ComputationalBiology #MolecularDynamics #Bioinformatics #ProteinStability #StructuralBiology

🧬 One amino acid to stabilize them all — myth or molecular reality?

🔗 Single-residue engineering of lambda (λ) antibody light chains reduces conformational flexibility and enhances thermal stability. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.10.045

📚 CSBJ: https://www.csbj.org/

#MonoclonalAntibodies #mAbs #Immunology #ComputationalBiology #MolecularDynamics #Bioinformatics #ProteinStability #StructuralBiology

Start today and end up with €700 for the big day – The Irish Times

Did someone mention Christmas? If you think it’s too early for the ‘C’ word, think again. We are…
#NewsBeep #News #Personalfinance #blackfriday #brown-thomas #Business #Christmas #cyber-monday #Finance #mabs-money-advice-and-budgeting-service #MoneyMatters #PersonalFinance #UK #UnitedKingdom
https://www.newsbeep.com/uk/203297/

Start today and end up with €700 for the big day – The Irish Times

Did someone mention Christmas? If you think it’s too early for the ‘C’ word, think again. We are…
#NewsBeep #News #Personalfinance #AU #Australia #blackfriday #brown-thomas #Business #Christmas #cyber-monday #Finance #mabs-money-advice-and-budgeting-service #moneymatters #PersonalFinance
https://www.newsbeep.com/au/215302/

@MaxionTherapeutics, not on #Bluesky, announces the completion of their $72M Series A. #biotech #mAbs #antibodies #channels #DrugDiscovery #Loxbridge

RE: https://bsky.app/profile/did:plc:oxh2lmowuusxjqn4f4usyjk5/post/3lkkzp4ocn22q

@MaxionTherapeutics, not on #Bluesky, announces the completion of their $72M Series A. #biotech #mAbs #antibodies #channels #DrugDiscovery #Loxbridge

RE: https://bsky.app/profile/did:plc:oxh2lmowuusxjqn4f4usyjk5/post/3lkkzp4ocn22q

@MaxionTherapeutics, not on #Bluesky, announces the completion of their $72M Series A. #biotech #mAbs #antibodies #channels #DrugDiscovery #Loxbridge

RE: https://bsky.app/profile/did:plc:oxh2lmowuusxjqn4f4usyjk5/post/3lkkzp4ocn22q

#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1

#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.

#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1

#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.

#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1

#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.

#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1

#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.

#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1

#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 {#mAbs} in Healthy #Adults for #Prevention of #Influenza A Illness (PENINSULA), Clin Infect Dis.: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae368/7717845?login=false

VIR-2482 1200 mg IM was well tolerated but did not significantly prevent protocol-defined ILI. Secondary endpoint analyses suggest this dose may have reduced influenza A illness.

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 {#mAbs} in Healthy #Adults for #Prevention of #Influenza A Illness (PENINSULA), Clin Infect Dis.: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae368/7717845?login=false

VIR-2482 1200 mg IM was well tolerated but did not significantly prevent protocol-defined ILI. Secondary endpoint analyses suggest this dose may have reduced influenza A illness.

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 {#mAbs} in Healthy #Adults for #Prevention of #Influenza A Illness (PENINSULA), Clin Infect Dis.: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae368/7717845?login=false

VIR-2482 1200 mg IM was well tolerated but did not significantly prevent protocol-defined ILI. Secondary endpoint analyses suggest this dose may have reduced influenza A illness.

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 {#mAbs} in Healthy #Adults for #Prevention of #Influenza A Illness (PENINSULA), Clin Infect Dis.: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae368/7717845?login=false

VIR-2482 1200 mg IM was well tolerated but did not significantly prevent protocol-defined ILI. Secondary endpoint analyses suggest this dose may have reduced influenza A illness.

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 {#mAbs} in Healthy #Adults for #Prevention of #Influenza A Illness (PENINSULA), Clin Infect Dis.: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae368/7717845?login=false

VIR-2482 1200 mg IM was well tolerated but did not significantly prevent protocol-defined ILI. Secondary endpoint analyses suggest this dose may have reduced influenza A illness.

[Articles] Effect of anti- #Ebola virus #mAbs on endogenous #antibody production in #survivors of #EVD in the #DRC: an observational cohort study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00552-2/fulltext?rss=yes

[Articles] Effect of anti- #Ebola virus #mAbs on endogenous #antibody production in #survivors of #EVD in the #DRC: an observational cohort study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00552-2/fulltext?rss=yes

[Articles] Effect of anti- #Ebola virus #mAbs on endogenous #antibody production in #survivors of #EVD in the #DRC: an observational cohort study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00552-2/fulltext?rss=yes

[Articles] Effect of anti- #Ebola virus #mAbs on endogenous #antibody production in #survivors of #EVD in the #DRC: an observational cohort study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00552-2/fulltext?rss=yes

[Articles] Effect of anti- #Ebola virus #mAbs on endogenous #antibody production in #survivors of #EVD in the #DRC: an observational cohort study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00552-2/fulltext?rss=yes

#Antigenicity and #receptor affinity of #SARS-CoV-2 #BA286 #spike, https://www.nature.com/articles/s41586-023-06750-w #research #variants #VOI #vaccines #mAbs

#Antigenicity and #receptor affinity of #SARS-CoV-2 #BA286 #spike, https://www.nature.com/articles/s41586-023-06750-w #research #variants #VOI #vaccines #mAbs

#Antigenicity and #receptor affinity of #SARS-CoV-2 #BA286 #spike, https://www.nature.com/articles/s41586-023-06750-w #research #variants #VOI #vaccines #mAbs

#Antigenicity and #receptor affinity of #SARS-CoV-2 #BA286 #spike, https://www.nature.com/articles/s41586-023-06750-w #research #variants #VOI #vaccines #mAbs

#Antigenicity and #receptor affinity of #SARS-CoV-2 #BA286 #spike, https://www.nature.com/articles/s41586-023-06750-w #research #variants #VOI #vaccines #mAbs

''Here, we demonstrate analogous humoral #antigen recognition between both MPXV-infected or #Smallpox-vaccinated individuals, with binding to diverse yet core set of #poxvirus antigens, providing opportunities for future vaccine (e.g., #mRNA) and therapeutic (e.g., #mAbs) design.''

''Here, we demonstrate analogous humoral #antigen recognition between both MPXV-infected or #Smallpox-vaccinated individuals, with binding to diverse yet core set of #poxvirus antigens, providing opportunities for future vaccine (e.g., #mRNA) and therapeutic (e.g., #mAbs) design.''

''Here, we demonstrate analogous humoral #antigen recognition between both MPXV-infected or #Smallpox-vaccinated individuals, with binding to diverse yet core set of #poxvirus antigens, providing opportunities for future vaccine (e.g., #mRNA) and therapeutic (e.g., #mAbs) design.''

''Here, we demonstrate analogous humoral #antigen recognition between both MPXV-infected or #Smallpox-vaccinated individuals, with binding to diverse yet core set of #poxvirus antigens, providing opportunities for future vaccine (e.g., #mRNA) and therapeutic (e.g., #mAbs) design.''

Impaired neutralizing #antibody #efficacy of #tixagevimab-cilgavimab 150+150 mg as pre-exposure #prophylaxis against #Omicron #BA5. A real-world experience in booster vaccinated immunocompromised patients, J Clin Virol.: https://doi.org/10.1016/j.jcv.2023.105584 #reseach #science #medicine #mAbs #betacoronavirus #sarbecovirus #covid19

Impaired neutralizing #antibody #efficacy of #tixagevimab-cilgavimab 150+150 mg as pre-exposure #prophylaxis against #Omicron #BA5. A real-world experience in booster vaccinated immunocompromised patients, J Clin Virol.: https://doi.org/10.1016/j.jcv.2023.105584 #reseach #science #medicine #mAbs #betacoronavirus #sarbecovirus #covid19

Impaired neutralizing #antibody #efficacy of #tixagevimab-cilgavimab 150+150 mg as pre-exposure #prophylaxis against #Omicron #BA5. A real-world experience in booster vaccinated immunocompromised patients, J Clin Virol.: https://doi.org/10.1016/j.jcv.2023.105584 #reseach #science #medicine #mAbs #betacoronavirus #sarbecovirus #covid19

Impaired neutralizing #antibody #efficacy of #tixagevimab-cilgavimab 150+150 mg as pre-exposure #prophylaxis against #Omicron #BA5. A real-world experience in booster vaccinated immunocompromised patients, J Clin Virol.: https://doi.org/10.1016/j.jcv.2023.105584 #reseach #science #medicine #mAbs #betacoronavirus #sarbecovirus #covid19

[Review] #Prevention and post- #exposure #management of occupational exposure to #Ebola virus https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00376-6/fulltext?rss=yes #research #science #medicine #filovirus #vaccines #antivirals #mAbs

[Review] #Prevention and post- #exposure #management of occupational exposure to #Ebola virus https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00376-6/fulltext?rss=yes #research #science #medicine #filovirus #vaccines #antivirals #mAbs

[Review] #Prevention and post- #exposure #management of occupational exposure to #Ebola virus https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00376-6/fulltext?rss=yes #research #science #medicine #filovirus #vaccines #antivirals #mAbs

#Safety and #efficacy of inhaled IBIO123 {#mAbs} for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial, Lancet Infect Dis., https://doi.org/10.1016/S1473-3099(23)00393-6 #research #covid19 #SARS_CoV_2 #medicine #science

#Safety and #efficacy of inhaled IBIO123 {#mAbs} for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial, Lancet Infect Dis., https://doi.org/10.1016/S1473-3099(23)00393-6 #research #covid19 #SARS_CoV_2 #medicine #science

#Safety and #efficacy of inhaled IBIO123 {#mAbs} for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial, Lancet Infect Dis., https://doi.org/10.1016/S1473-3099(23)00393-6 #research #covid19 #SARS_CoV_2 #medicine #science

''... the #IgM #mAbs could potentially be used for prevention or treatment of #EV-A71 infections.''

''... the #IgM #mAbs could potentially be used for prevention or treatment of #EV-A71 infections.''

''... the #IgM #mAbs could potentially be used for prevention or treatment of #EV-A71 infections.''

@failedLyndonLaRouchite
Absolutely. #mAbs are a net plus, certainly for the person.

@failedLyndonLaRouchite
Absolutely. #mAbs are a net plus, certainly for the person.

@failedLyndonLaRouchite
Absolutely. #mAbs are a net plus, certainly for the person.

@failedLyndonLaRouchite
Absolutely. #mAbs are a net plus, certainly for the person.